A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer

Background: Accumulating literature demonstrates that long noncoding RNAs (lncRNAs) are involved in ferroptosis and gastric cancer progression. However, the predictive value of ferroptosis-related lncRNAs for prognosis and therapeutic response is yet to be elucidated in gastric cancer (GC).Method: T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shilang Xiao, Xiaoming Liu, Lingzhi Yuan, Fen Wang
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/5cb56a93c873495288fa6534df6f942d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5cb56a93c873495288fa6534df6f942d
record_format dspace
spelling oai:doaj.org-article:5cb56a93c873495288fa6534df6f942d2021-12-02T10:40:50ZA Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer2296-634X10.3389/fcell.2021.736682https://doaj.org/article/5cb56a93c873495288fa6534df6f942d2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcell.2021.736682/fullhttps://doaj.org/toc/2296-634XBackground: Accumulating literature demonstrates that long noncoding RNAs (lncRNAs) are involved in ferroptosis and gastric cancer progression. However, the predictive value of ferroptosis-related lncRNAs for prognosis and therapeutic response is yet to be elucidated in gastric cancer (GC).Method: The transcriptomic data and corresponding clinical information of GC patients were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. The association between ferroptosis-related lncRNAs and ferroptosis regulators was analyzed by Spearman correlation analysis. Then, we established a risk predictive model based on the ferroptosis-related lncRNAs using multivariate Cox regression analysis. Furthermore, we performed correlation analysis for the risk score and characteristics of biological processes, immune landscape, stromal activity, genomic integrity, drug response, and immunotherapy efficacy.Results: We constructed a 17-ferroptosis-related-lncRNA signature via multivariate Cox analysis to divide patients into two groups: low- and high-risk groups. The low-risk group was linked to prolonged overall survival and relapse-free survival. The risk score had good predictive ability to predict the prognosis of GC patients compared with other clinical biomarkers. We found that the high-risk group was associated with activation of carcinogenetic signaling pathways, including stromal activation, epithelial-mesenchymal-transition (EMT) activation, and immune escape through integrated bioinformatics analysis. In contrast, the low-risk group was associated with DNA replication, immune-flamed state, and genomic instability. Additionally, through Spearman correlation analysis, we found that patients in the high-risk group may respond well to drugs targeting cytoskeleton, WNT signaling, and PI3K/mTOR signaling, and drugs targeting chromatin histone acetylation, cell cycle, and apoptosis regulation could bring more benefits for the low-risk group. The high-risk group was associated with poor immunotherapy efficacy.Conclusion: Our study systematically evaluated the role of ferroptosis-related lncRNAs in t tumor microenvironment, therapeutic response, and prognosis of GC. Risk score–based stratification could reflect the characteristic of biological processes, immune landscape, stromal activity, genomic stability, and pharmaceutical profile in GC patients. The ferroptosis-related lncRNA signature could serve as a reliable biomarker to predict prognosis and therapeutic response of patients with GC.Shilang XiaoShilang XiaoXiaoming LiuXiaoming LiuLingzhi YuanLingzhi YuanFen WangFen WangFrontiers Media S.A.articlegastric cancerferroptosislncRNAstromalimmune microenvironmenttherapeutic responseBiology (General)QH301-705.5ENFrontiers in Cell and Developmental Biology, Vol 9 (2021)
institution DOAJ
collection DOAJ
language EN
topic gastric cancer
ferroptosis
lncRNA
stromal
immune microenvironment
therapeutic response
Biology (General)
QH301-705.5
spellingShingle gastric cancer
ferroptosis
lncRNA
stromal
immune microenvironment
therapeutic response
Biology (General)
QH301-705.5
Shilang Xiao
Shilang Xiao
Xiaoming Liu
Xiaoming Liu
Lingzhi Yuan
Lingzhi Yuan
Fen Wang
Fen Wang
A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
description Background: Accumulating literature demonstrates that long noncoding RNAs (lncRNAs) are involved in ferroptosis and gastric cancer progression. However, the predictive value of ferroptosis-related lncRNAs for prognosis and therapeutic response is yet to be elucidated in gastric cancer (GC).Method: The transcriptomic data and corresponding clinical information of GC patients were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. The association between ferroptosis-related lncRNAs and ferroptosis regulators was analyzed by Spearman correlation analysis. Then, we established a risk predictive model based on the ferroptosis-related lncRNAs using multivariate Cox regression analysis. Furthermore, we performed correlation analysis for the risk score and characteristics of biological processes, immune landscape, stromal activity, genomic integrity, drug response, and immunotherapy efficacy.Results: We constructed a 17-ferroptosis-related-lncRNA signature via multivariate Cox analysis to divide patients into two groups: low- and high-risk groups. The low-risk group was linked to prolonged overall survival and relapse-free survival. The risk score had good predictive ability to predict the prognosis of GC patients compared with other clinical biomarkers. We found that the high-risk group was associated with activation of carcinogenetic signaling pathways, including stromal activation, epithelial-mesenchymal-transition (EMT) activation, and immune escape through integrated bioinformatics analysis. In contrast, the low-risk group was associated with DNA replication, immune-flamed state, and genomic instability. Additionally, through Spearman correlation analysis, we found that patients in the high-risk group may respond well to drugs targeting cytoskeleton, WNT signaling, and PI3K/mTOR signaling, and drugs targeting chromatin histone acetylation, cell cycle, and apoptosis regulation could bring more benefits for the low-risk group. The high-risk group was associated with poor immunotherapy efficacy.Conclusion: Our study systematically evaluated the role of ferroptosis-related lncRNAs in t tumor microenvironment, therapeutic response, and prognosis of GC. Risk score–based stratification could reflect the characteristic of biological processes, immune landscape, stromal activity, genomic stability, and pharmaceutical profile in GC patients. The ferroptosis-related lncRNA signature could serve as a reliable biomarker to predict prognosis and therapeutic response of patients with GC.
format article
author Shilang Xiao
Shilang Xiao
Xiaoming Liu
Xiaoming Liu
Lingzhi Yuan
Lingzhi Yuan
Fen Wang
Fen Wang
author_facet Shilang Xiao
Shilang Xiao
Xiaoming Liu
Xiaoming Liu
Lingzhi Yuan
Lingzhi Yuan
Fen Wang
Fen Wang
author_sort Shilang Xiao
title A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
title_short A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
title_full A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
title_fullStr A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
title_full_unstemmed A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer
title_sort ferroptosis-related lncrnas signature predicts prognosis and therapeutic response of gastric cancer
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/5cb56a93c873495288fa6534df6f942d
work_keys_str_mv AT shilangxiao aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT shilangxiao aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT xiaomingliu aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT xiaomingliu aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT lingzhiyuan aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT lingzhiyuan aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT fenwang aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT fenwang aferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT shilangxiao ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT shilangxiao ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT xiaomingliu ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT xiaomingliu ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT lingzhiyuan ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT lingzhiyuan ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT fenwang ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
AT fenwang ferroptosisrelatedlncrnassignaturepredictsprognosisandtherapeuticresponseofgastriccancer
_version_ 1718396830066147328